Department of ENT, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia, 010017, China.
Iran J Immunol. 2020 Dec;17(4):283-291. doi: 10.22034/iji.2020.84336.1652.
Vitamin D supplementation has been proven to be effective in the treatment of allergic rhinitis (AR).
We conducted the present study to explore the role and efficacy of vitamin D adjuvant therapy for the treatment of inflammation in patients with AR.
Out of 127 patients with potential eligible AR, 60 were randomly assigned into two groups and were finally included in our analysis (n=30 for each intervention). The patients with potential eligible AR were randomly allocated to intervention with desloratadine citrate disodium (DCD, 8.8 mg/day) without and with vitamin D3 nasal drops (1.5х106 IU, once/week) for four weeks. Thirty healthy control subjects were included in our study. We assessed the changes in the serum 25(OH)D, peripheral blood eosinophils, interleukin (IL)-4 levels, and nasal symptoms. Serum 25(OH)D, peripheral blood eosinophils, and IL-4 levels were detected respectively with liquid chromatography-tandem mass spectrometry (LC-MS/MS), a blood detector, and enzyme-linked immunosorbent assay.
Our patients who received vitamin D3 adjuvant therapy had a higher serum 25(OH)D level (47.57 ± 2.83 vs. 31.51 ± 2.95 ng/ml, p=0.000) and lower AR symptoms score (2.07 ± 1.89 vs. 3.37 ± 1.50, p=0.005), serum IL-4 (10.38 ± 3.41 vs. 12.79 ± 5.40 pg/ml, p=0.043), and peripheral blood eosinophils (0.34 ± 0.09 vs. 0.41 ± 0.10 109/l, p=0.003) compared with DCD single treatment. The efficacy rates of DCD with and without vitamin D3 in AR were 97% and 84%, respectively.
Nasal vitamin D3 combined with DCD could improve the clinical symptoms of AR. Vitamin D3 adjunct therapy showed significant effects on inhibiting inflammation in patients with AR. We concluded that vitamin D3 supplementation could be an effective adjuvant therapy in AR patients.
维生素 D 补充剂已被证明可有效治疗过敏性鼻炎 (AR)。
本研究旨在探讨维生素 D 辅助治疗在治疗 AR 患者炎症中的作用和疗效。
在 127 例潜在合格的 AR 患者中，60 例随机分为两组，最终纳入分析（每组 n=30）。将潜在合格的 AR 患者随机分配至干预组，给予枸橼酸地氯雷他定（DCD，8.8 mg/天）治疗，联合和不联合维生素 D3 滴鼻剂（1.5х106 IU，每周一次）治疗 4 周。纳入 30 例健康对照者。我们评估了血清 25(OH)D、外周血嗜酸性粒细胞、白细胞介素 (IL)-4 水平和鼻部症状的变化。分别采用液相色谱-串联质谱法 (LC-MS/MS)、血液检测仪和酶联免疫吸附法检测血清 25(OH)D、外周血嗜酸性粒细胞和 IL-4 水平。
接受维生素 D3 辅助治疗的患者血清 25(OH)D 水平更高（47.57 ± 2.83 vs. 31.51 ± 2.95 ng/ml，p=0.000），AR 症状评分更低（2.07 ± 1.89 vs. 3.37 ± 1.50，p=0.005），血清 IL-4（10.38 ± 3.41 vs. 12.79 ± 5.40 pg/ml，p=0.043）和外周血嗜酸性粒细胞（0.34 ± 0.09 vs. 0.41 ± 0.10×109/l，p=0.003）低于 DCD 单药治疗。DCD 联合和不联合维生素 D3 治疗 AR 的有效率分别为 97%和 84%。
鼻用维生素 D3 联合 DCD 可改善 AR 的临床症状。维生素 D3 辅助治疗对抑制 AR 患者炎症具有显著疗效。我们得出结论，维生素 D3 补充剂可作为 AR 患者的有效辅助治疗方法。
